| Literature DB >> 35739459 |
Joshua Mountford1, Almas Gheyas1, Lonneke Vervelde1, Jacqueline Smith1.
Abstract
Avian viruses of economic interest are a significant burden on the poultry industry, affecting production traits and resulting in mortality. Furthermore, the zoonosis of avian viruses risks pandemics developing in humans. Vaccination is the most common method of controlling viruses; however current vaccines often lack cross-protection against multiple strains of each virus. The mutagenicity of these viruses has also led to virulent strains emerging that can overcome the protection offered by vaccines. Breeding chickens with a more robust innate immune response may help in tackling current and emerging viruses. Understanding the genetic evolution of different lines will thus provide a useful tool in helping the host in the fight against pathogens. This study focuses on the interferon genes and their receptors in different chicken lines that are known to be more resistant or susceptible to particular avian viruses. Comparing genotypic differences in these core immune genes between the chicken lines may explain the phenotypic differences observed and aid the identification of causative variations. The relative resistance/susceptibility of each line to viruses of interest (Marek's disease virus, infectious bursal disease, infectious bronchitis virus and avian influenza virus) has previously been determined. Here we identify single nucleotide polymorphisms in interferons and downstream genes. Functional prediction tools were used to identify variants that may be affecting protein structure, mRNA secondary structure or transcription factor and micro-RNA binding sites. These variants were then considered in the context of the research lines and their distribution between phenotypes. We highlight 60 variants of interest in the interferon pathway genes that may account for susceptibility/resistance to viral pathogens.Entities:
Keywords: chicken; disease resistance; genetic variation; inbred lines; interferon
Mesh:
Substances:
Year: 2022 PMID: 35739459 PMCID: PMC9544680 DOI: 10.1111/age.13233
Source DB: PubMed Journal: Anim Genet ISSN: 0268-9146 Impact factor: 2.884
FIGURE 1The current model for the interferon response pathway of the chicken. Type I, II and III interferon molecules act as cytokines in a paracrine and autocrine fashion by interacting with the IFNAR1:IFNAR2, IFNGR1:IFNGR2 and IFNLR1:IL‐10Rβ dimeric receptor complexes respectively. Upon receptor binding, the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway is activated, whereby phosphorylation of STAT1 and STAT2 causes them to dimerise. In mammals this dimer then goes on to form the complex interferon stimulated gene factor 3 (ISGF3 – in mammals this complex forms via interactions with IRF9, however a chicken orthologue of this protein has yet to be identified). The ISGF3 complex can then enter the nucleus and bind to interferon stimulated response element sequences, resulting in the upregulation of hundreds of ISGs and a specific antiviral state. In the case of the type II system, STAT1 and STAT2 form a homodimer that can then enter the nucleus and bind to gamma‐activated sequences, resulting in upregulation of specific ISGs (Andreakos et al., 2019; Santhakumar et al., 2017b). This image was created using modified images from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License (http://smart.servier.com)
Resistant and susceptible phenotypes of research lines
| Inbred chicken line | MHC B haplotype | Virus resistance phenotype (Resistant/Moderate susceptibility/Susceptible) | |||
|---|---|---|---|---|---|
| IBV (Bumstead et al., | IBDV (Asfor et al., | MDV (Burgess et al., | LPAIV (Ruiz‐Hernandez et al., | ||
| Wl | B14 | M | S | – | – |
| 15I | B15 | S | R | S | – |
| 72 | B2 | S | R | S | – |
| 61 | B2 | M | M | R | – |
| C | B4 and B12 | R | R | – | S |
| N | B21 | R | M | R | – |
| 0 | B21 | – | R | – | R |
| P2a | B19 | – | – | S | – |
LPAIV ‐ Lowly Pathogenic Avian Influenza Virus; “R” denotes resistance, “M” denotes moderate susceptibility, “S” denotes susceptibility and “–” indicates no data identified.
These data do not account for potential gender differences.
These lines were originally housed at the Institute for Animal Health, Compton, UK, but are now available at the NARF, Roslin, UK.
Genes of interest identified in GRCg6a
| Gene | Gene/paralogue ID | Sequence location and direction |
|---|---|---|
|
| ENSGALG00000052146 | Chromosome 7: 4610682‐4 612 191 forward strand |
| ENSGALG00000050947 | Chromosome 7: 4572389‐4 573 897 forward strand | |
| ENSGALG00000047344 | Chromosome 7: 4591535‐4 593 042 forward strand | |
|
| ENSGALG00000048874 | Chromosome Z: 7395233‐7 395 995 forward strand |
| ENSGALG00000052209 | Chromosome Z: 7410282‐7 411 044 forward strand | |
| ENSGALG00000044725 | Chromosome Z: 7399231‐7 399 942 forward strand | |
| ENSGALG00000047630 | Chromosome Z: 7381503‐7 382 265 forward strand | |
| E | Chromosome Z: 7401271‐7 402 033 forward strand | |
| ENSGALG00000053752 | Chromosome Z: 7387284‐7 388 046 forward strand | |
| ENSGALG00000054396 | Chromosome Z: 7385475‐7 386 237 forward strand | |
| ENSGALG00000046996 | Chromosome Z: 7377531‐7 378 293 forward strand | |
| ENSGALG00000053207 | Chromosome Z: 7414251‐7 415 013 forward strand | |
| ENSGALG00000054368 | Chromosome Z: 7391261‐7 392 023 forward strand | |
| ENSGALG00000054104 | Chromosome Z: 7421956‐7 422 718 forward strand | |
|
| ENSGALG00000005759 | Chromosome Z: 7372029‐7 372 640 forward strand |
|
| ENSGALG00000015062 | Chromosome Z: 34282011‐34 285 224 reverse strand |
|
| ENSGALG00000009903 | Chromosome 1: 35173604‐35 177 772 reverse strand |
|
| ENSGALG00000030363 | Chromosome 1: 106613562‐106 632 348 forward strand |
|
| ENSGALG00000041867 | Chromosome 1: 106580169‐106 592 227 forward strand |
|
| ENSGALG00000004231 | Chromosome 23: 5819774–5 826 643 reverse strand |
|
| ENSGALG00000037989 | Chromosome 1: 106593970‐106 604 799 forward strand |
|
| ENSGALG00000013865 | Chromosome 3: 54895190‐54 914 161 forward strand |
|
| ENSGALG00000032660 | Chromosome 1: 106645075‐106 653 536 forward strand |
|
| ENSGALG00000030599 | Chromosome 30: 178603–197 548 forward strand |
|
| ENSGALG00000011031 | Chromosome 8: 28552333‐28 603 383 reverse strand |
|
| ENSGALG00000015027 | Chromosome Z: 27532087‐27 615 380 forward strand |
|
| ENSGALG00000007651 | Chromosome 7: 7912708‐7 932 691 reverse strand |
|
| ENSGALG00000030661 | Chromosome 33: 6934615‐6 940 207 forward strand |
|
| ENSGALG00000030291 | Chromosome 20: 10063682‐10 066 572 reverse strand |
Distribution of SNPs in genes of interest across lines
| Distribution of SNPs in genes of interest across lines | Upstream | Downstream | 5′UTR | 3′UTR | Intronic SNPs | Synonymous SNPs | Missense SNPs | ||
|---|---|---|---|---|---|---|---|---|---|
| Gene affected | Transcript ID | Total SNPs in gene (±1 kb) | |||||||
|
|
| 53 | 6 | 13 | 0 | 2 | 32 | 0 | 0 |
|
|
| 8 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
|
|
| 10 | 3 | 5 | 0 | 0 | 0 | 1 | 1 |
|
|
| 9 | 1 | 1 | 0 | 2 | 4 | 1 | 0 |
|
|
| 208 | 9 | 13 | 1 | 15 | 160 | 4 | 6 |
|
|
| 185 | 20 | 16 | 1 | 6 | 133 | 1 | 8 |
|
|
| 16 | 1 | 1 | 2 | 1 | 7 | 1 | 3 |
|
|
| 169 | 18 | 12 | 0 | 7 | 126 | 2 | 4 |
|
|
| 163 | 9 | 8 | 1 | 7 | 136 | 0 | 2 |
|
|
| 85 | 5 | 13 | 0 | 11 | 53 | 2 | 1 |
|
|
| 23 | 0 | 1 | 0 | 0 | 15 | 1 | 6 |
|
|
| 626 | 11 | 5 | 2 | 1 | 591 | 14 | 2 |
|
|
| 143 | 2 | 1 | 0 | 0 | 136 | 4 | 0 |
|
|
| 21 | 3 | 0 | 0 | 0 | 17 | 0 | 1 |
|
|
| 12 | 0 | 2 | 0 | 0 | 7 | 3 | 0 |
|
|
| 29 | 5 | 0 | 0 | 0 | 15 | 7 | 2 |
| Total SNPs | 1760 | 101 | 91 | 7 | 52 | 1432 | 41 | 36 | |
| SNP % distribution | 5.74 | 5.17 | 0.398 | 2.95 | 81.4 | 2.33 | 2.05 | ||
The low number of identified SNPs may be a reflection of the low sequence coverage in these regions.
Missense SNPs in genes of interest identified in chicken lines
| SNP genome coordinate | Protein affected | Line(s) in which SNP is present | Alleles (ref/SNP) | Amino acid substitution | SIFT score | PROVEAN score | SNAP2 score | Comments on SNP location |
|---|---|---|---|---|---|---|---|---|
| Chr1:106,613,646 | IFNAR1 | 61, 72, 0 | G/A | A4T | 0 | 0.012 | −84 | |
| Chr1:106,613,656 | IFNAR1 | 72 | C/T | A7V | 0 | 0.647 | −25 | |
| Chr1:106,621,892 | IFNAR1 | 15I, 61, 72, C, N, P2a | T/G | Y217D | 0.29 | 0.363 |
| Occurs in FN3 domain |
| Chr1:106,621,899 | IFNAR1 | N | A/G | E219G | 0.44 | −0.719 |
| Occurs in FN3 domain |
| Chr1:106,623,894 | IFNAR1 | 15I, 61, 72, C, N, 0, Wl | G/A | S324N | 1 | 1.099 | −81 | Occurs in tissue factor domain |
| Chr1:106,625,990 | IFNAR1 | 0 | C/T | A404V | 0.76 | 0.729 | −87 | Occurs in interferon binding domain |
| Chr1:106,587,598 | IFNAR2 | C | C/T | P45S | 0 | 0.759 | −78 | Occurs in tissue factor domain |
| Chr1:106,588,380 | IFNAR2 | 15I, 72, C, 0 | C/T | H137Y | 1 | 0.037 | −65 | |
| Chr1:106,588,700 | IFNAR2 | 15I, 72, P2a | A/G | N188D | 0.7 | −0.238 | −89 | Occurs in interferon binding domain |
| Chr1:106,589,401 | IFNAR2 | 15I, P2a | T/C | I214T | 0.11 | −0.435 | −68 | Occurs in interferon binding domain |
| Chr1:106,589,970 | IFNAR2 | 15I, C, P2a | G/T | G264V | 0.15 | 0.584 | −1 | Occurs in transmembrane region |
| Chr1:106,590,778 | IFNAR2 | 15I, C, P2a | A/G | I296V | 1 | −0.005 | −75 | |
| Chr1:106,591,040 | IFNAR2 | 15I, C, P2a | G/A | G383D | 0.69 | 1.243 | −29 | |
| Chr1:106,591,349 | IFNAR2 | 15I, C, P2a | C/T | T486M | aa0 | −0.991 | −62 | |
| Chr3:54,913,306 | IFNGR1 | 15I, 61, 72, C, 0, Wl | T/C | V395A | 0.27 | −0.16 | −16 | |
| Chr3:54,913,327 | IFNGR1 | 15I, 61, 72, C, 0, Wl | G/A | R402Q | 0.48 | 1.272 | −71 | |
| Chr1:106,647,185 | IFNGR2 | 61 | T/C | C44R | 0.62 | 3.391 | −60 | Occurs in tissue factor domain |
| Chr23:5,823,279 | IFNLR1 | N | T/C | E151G | 0 | −1.341 | −19 | Occurs in interferon binding domain |
| Chr23:5,822,624 | IFNLR1 | C | A/G | S199P | 0.23 | −1.046 |
| Occurs in interferon binding domain |
| Chr23:5,822,588 | IFNLR1 | 72
| A/G | S211P | 0.06 | − |
| Occurs in interferon binding domain |
| Chr1:106,602,130 | IL10RB | 61 | T/G | S248A | 1 | 0.375 | −66 | |
| Chr1:106,603,837 | IL10RB | 61, 72, N, P2a | A/T | Q293H |
| −1.17 | −95 | |
| Chr1:106,603,910 | IL10RB | 72 | A/G | R318G | 0.38 | −0.716 |
| |
| Chr1:106,603,911 | IL10RB | C, P2a | G/A | R318K | 1 | −0.092 | −78 | |
| ChrZ:7,372,479 | IFNβ | N | T/C | S151P | 0.36 | −1.728 |
| Occurs in IFNα/β/δ domain |
| Chr7:7,923,855 | STAT1 | 15I | A/C | V341G | 0.03 | − |
| Occurs in STAT binding domain |
| Chr8:28,566,979 | JAK1 | N | A/G | V332A | 0.67 | −0.305 | −67 | |
| Chr8:28,564,446 | JAK1 | C | A/C | Y500D |
| − |
| Occurs in SH2 domain |
| Chr30:182,787 | TYK2 | 72
| A/C | H215P | 0.2 | − |
| Occurs in B41 domain |
| Chr30:183,686 | TYK2 | 15I | G/A | R299Q | 0.44 | −0.551 | −17 | Occurs in B41 domain |
| Chr30:186,858 | TYK2 | 72
| T/C | V550A |
| − | −26 | Occurs in SH2 domain |
| Chr30:190,505 | TYK2 | 61, 72, P2a, 0 | G/A | S875N | 0.45 | 0.351 | −96 | Occurs in TyrKc domain |
| Chr30:190,528 | TYK2 | C | T/C | S883P | 0.25 | − |
| Occurs in TyrKc domain |
| Chr30:190,801 | TYK2 | 61
| A/C | D908A | 0.34 | −1.029 | −53 | |
| Chr20:10,064,956 | IRF9 | P2a | T/C | H186R | 0.51 | −1.24 | −38 | |
| Chr20:10,064,260 | IRF9 | 61
| T/G | Y355S | 0.15 | − |
| Occurs in IRF‐3 domain |
Scores in bold indicate a predicted significant effect.
SNP occurs in only one allele and is therefore heterozygous.
SIFT scores with low confidence in the value due to too few comparable sequences for the software to make a reliable prediction.
FIGURE 2Location of missense SNPs with regards to predicted protein domains. (a) IFNAR1 – Y217, E219G and A404V can be found in fibronectin type 3 (FN3) domains. (b) IFNAR2 – P45S occurs in a tissue factor domain, N188D and I214T occur in an interferon binding domain and G264V occurs in the transmembrane region. (c) IFNGR1 – no SNPs were identified in the predicted domains. (d) IFNGR2 – C44R in tissue factor domain. (e) IFNLR1 – E151G, S199P and S211P occur in an interferon binding domain. (f) IL10Rβ – no SNPs were identified in predicted domains. (g) IFNβ – S151P SNP occurs in an IFNα/β/δ domain. (h) STAT1 – V341G SNP occurs in a STAT binding domain. (i) JAK1 – Y500D occurs in an Src Homolog 2 (SH2) domain. (j) TYK2 – H215P and R299Q occur in a band 4.1 (B41) domain and S875N, S883P and D908A occur in tyrosine kinase catalytic domains (TyrKc). (k) IRF9 – Y335S occurs in an interferon regulatory factor 3 (IRF3) domain. Note, chickens lack IRF3 but have an IRF7 orthologue. IFαβδ, Interferon alpha, beta and delta domain; STAT_int, STAT protein interaction domain; STAT_alpha, STAT protein all‐alpha domain; STAT_bind, STAT protein DNA binding domain; B41, band 4.1 homologue domain (also known as ERM domain, erzin/radixin/moesin domain); STYKc, protein kinase of unclassified specificity; IRF, interferon regulatory factor domain. Pink indicates low complexity regions and dark blue blocks signify transmembrane regions
SNPs of interest predicted to potentially perturb mRNA secondary structure
| SNP genome coordinate | mRNA affected | Line(s) in which SNP is present | Alleles (ref/SNP) | mRNA base change | RNAsnp P‐value | SNPfold P‐value | Region affected |
|---|---|---|---|---|---|---|---|
| Chr1:106613656 |
| 72 | C/T | C/U | 0.4067 |
| Exonic |
| Chr1:106622867 |
| N, 0 | C/T | C/U | 0.6077 |
| Exonic |
| Chr1:106623894 |
| 15I, 61, 72, C, N, 0, Wl | G/A | G/A |
| 0.4078 | Exonic |
| Chr1:106625990 |
| 0 | C/T | C/U | 0.5257 |
| Exonic |
| Chr1:106631527 |
| P2a | G/A | G/A | 0.8683 |
| 3′UTR |
| Chr1:106632281 |
| 15I, 61, 72, C, N, P2a | T/C | U/C | 0.9474 |
| 3′UTR |
| Chr1:106589970 |
| 15I, C, P2a | G/T | G/U | 0.424 |
| Exonic |
| Chr1:106592036 |
| 15I, C, 0, Wl | T/G | U/G | 0.5046 |
| 3′UTR |
| Chr3:54913306 |
| 15I, 61, 72, C, 0, Wl | T/C | U/C |
| 0.3036 | Exonic |
| Chr1:106652516 |
| N, 0 | G/A | G/A | 0.9103 |
| 3′UTR |
| Chr1:106653379 |
| N, 0 | C/T | C/U | 0.1912 |
| 3′UTR |
| Chr23:5823279 |
| N | T/C | A/G |
| 0.3326 | Exonic |
| Chr1:106604195 |
| 72
| T/G | U/G |
| 0.2181 | 3′UTR |
| Chr1:106604577 |
| 15I, 0 | G/A | G/A |
| 0.3225 | 3′UTR |
| ChrZ:34282637 |
| 61, 72, N, P2a, 0, Wl | C/T | G/A |
|
| 3′UTR |
| Chr8:28553812 |
| 15I, 72, C, N | G/A | C/U |
| 0.591 | Exonic |
| Chr8:28559109 |
| C | A/G | U/C |
| 0.4255 | Exonic |
| Chr8:28564450 |
| 15I, 61, 72, C, N | T/G | A/C |
| 0.4388 | Exonic |
| Chr8:28566979 |
| N | A/G | U/C | 0.1547 |
| Exonic |
| Chr8:28567177 |
| P2a | T/C | A/G | 0.7025 |
| Exonic |
| Chr8:28576480 |
| N | C/T | G/A |
| 0.3395 | Exonic |
Allele changes are listed for the forward strand; IFNLR1, IFNκ and JAK1 are found on the reverse strand so the mRNA base changes observed in these genes reflect that of the template strand.
Scores in bold can be considered significant (p > 0.1), # – scores still significant after Bonferroni correction.
SNP occurs in only one allele and is therefore heterozygous.
SNPs of interest predicted to affect TF or miRNA binding sites
| SNP genome coordinate | Gene/mRNA affected | Line(s) in which SNP is present | Alleles (ref/SNP) | mRNA base change | Comments |
|---|---|---|---|---|---|
| Chr1:106631586 |
| 0 | C/T | C/U | Identified as gga‐miR‐1627‐3p binding site |
| Chr1:106632281 |
| 15I, 61, 72, C, N, P2a | T/C | U/C | Identified as gga‐miR‐196‐1‐3p binding site |
| Chr7:7933106 |
| 61, C, P2a | C/T | N/A | Identified as V‐MAF TF binding site |
SNP occurs in only one allele and is therefore heterozygous.
SNPs of interest correlating with resistance or susceptibility against more than one virus
| SNP genome coordinate | Gene/mRNA affected | Phenotype (resistant/susceptible) | Virus affected (line with phenotype) | Comments |
|---|---|---|---|---|
| Chr1:106603837 |
| Resistant |
AIV (0) IBDV (72, 15L) MDV (N, 61) |
Significant SIFT score of 0.04 Heterozygous in line 0 |
| Chr1:106621899 |
| Resistant |
IBV (N) MDV (N) | Significant SNAP2 score of 18 |
| Chr1:106622867 |
| Resistant |
AIV (0) IBDV (0) IBV (N) MDV (N) |
SNPfold P‐value = 0.016 – significant after Bonferroni correction for Heterozygous in line 0 |
| Chr1:106625990 |
| Resistant |
AIV (0) IBDV (0) |
SNPfold P‐value = 0.0808 – not significant after applying Bonferroni correction Heterozygous in line 0 |
| Chr1:106652516 |
| Resistant |
AIV (0) IBDV (0) IBV (N) MDV (N) |
SNPfold P‐value = 0.0198 – not significant after applying Bonferroni correction Heterozygous in line 0 |
| Chr1:106653379 |
| Resistant |
AIV (0) IBDV (0) IBV (N) MDV (N) |
SNPfold P‐value = 0.0473 – not significant after applying Bonferroni correction Heterozygous in line 0 |
| Chr23:5823279 |
| Resistant |
IBV (N) MDV (N) |
SNPfold P‐value = 0.0811 – not significant after applying Bonferroni correction Heterozygous in line N |
| Chr8:28566979 |
| Resistant |
IBDV (0) AIV (0) IBV (N) |
SNPfold P‐value = 0.0105 – not significant after applying Bonferroni correction Heterozygous in line N |
| Chr8:28576480 |
| Resistant |
AIV (0) IBDV (0) IBV (N) |
RNAsnp P‐value = 0.051 – not significant after applying Bonferroni correction Heterozygous in line N |
| ChrZ:7372479 |
| Resistant |
IBV (N) MDV (N) |
Significant SNAP2 score of 52 Heterozygous in line N |
| Chr1:106588380 |
| Susceptible |
MDV (15L, 72) AIV (C) | No impact calculated by functional prediction tools |
| Chr1:106589970 |
| Susceptible |
MDV (15L, P2a) AIV (C) IBDV (Wl) |
SNPfold Heterozygous in line P2a |
| Chr1:106590778 |
| Susceptible |
MDV (15L, P2a) IBDV (Wl) |
No impact calculated by functional prediction tools Heterozygous in line P2a |
| Chr1:106591040 |
| Susceptible |
MDV (15L, P2a) AIV (C) IBDV (Wl) |
No impact calculated by functional prediction tools Heterozygous in line P2a |
| Chr1:106591349 |
| Susceptible |
MDV (15L, P2a) IBDV (Wl) |
No impact calculated by functional prediction tools Heterozygous in line P2a |
| Chr1:106592036 |
| Susceptible |
MDV (15L) IBDV (Wl) | SNPfold P‐value = 0.0275 – not significant after applying Bonferroni correction |
| Chr30:182787 |
| Susceptible |
IBV (72) MDV (72) IBDV (Wl) |
Significant PROVEAN score of −2.732 and significant SNAP2 score of 63 Heterozygous in lines 72 and Wl |
| Chr7:7923855 |
| Susceptible |
IBV (15L, 72) MDV (15L, 72) IBDV (Wl) |
Significant PROVEAN score of −4.766 and significant SNAP2 score of 39 Heterozygous in lines 15L, 72 and Wl |
| Chr8:28564450 |
| Susceptible |
AIV (C) IBDV (Wl) | RNAsnp P‐value = 0.0972 – not significant after applying Bonferroni correction |